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ABBREVIATION LIST 
 
BNP: brain natriuretic peptide 
CI: confidence interval 
COX: cyclooxygenase 
CT: computed tomography 
HFABP: heart-type fatty acid-binding protein 
IVC: inferior vena cava 
LMWH: low-molecular weigh heparin 
NSAIDs: nonsteroidal anti-inflammatory drugs 
PE: pulmonary embolism 
RV: right ventricle 
SD: standard deviation 
TIPES: Tenecteplase Italian Pulmonary Embolism Study 
UFH: unfractionated heparin 
V/Q: ventilation-perfusion 
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ABSTRACT 
 
Background: The inflammatory response associated with acute pulmonary 
embolism (PE) contributes to the development of right ventricular (RV) 
dysfunction. Nonsteroidal anti-inflammatory drugs (NSAIDs) may facilitate the 
reversal of PE-associated RV dysfunction. 
 
Methods: We randomly assigned normotensive patients who had acute PE 
associated with echocardiographic RV dysfunction and normal systemic blood 
pressure to receive intravenous (IV) diclofenac (two doses of 75 mg in the first 24 
hours after diagnosis) or IV placebo. All patients received standard 
anticoagulation with subcutaneous low-molecular-weight heparin (LMWH) and an 
oral vitamin K antagonist. RV dysfunction was defined by the presence of, at 
least, two of the following criteria: i) RV diastolic diameter > 30 mm in the 
parasternal window; ii) RV diameter > left ventricle diameter in the apical or 
subcostal space; iii) RV free wall hypokinesis; and iv) estimated pulmonary artery 
systolic pressure > 30 mm Hg. Persistence of RV dysfunction at 48 hours and 7 
days after randomization were the primary and secondary efficacy outcomes, 
respectively. The primary safety outcome was major bleeding within 7 days after 
randomization. 
 
Results: Of the 34 patients randomly assigned to diclofenac (17) or placebo (17), 
the intention-to-treat analysis showed persistent RV dysfunction at 48 hours in 
59% (95% confidence interval [CI], 33-82%) of the diclofenac group and in 76% 
(95% CI, 50-93%) of the placebo group (difference in risk [diclofenac minus 
standard anticoagulation], -17 percentage points; 95% CI, -47 to 17). Similar 
proportions (35%) of patients in the diclofenac and placebo groups had persistent 
RV dysfunction at 7 days. Major bleeding occurred in none of patients in the 
diclofenac group and in 5.9% (95% CI, 0.2-29%) of patient in the placebo group. 
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Conclusions: Due to slow recruitment, our study is inconclusive as to a potential 
benefit of diclofenac over placebo to reverse RV dysfunction in normotensive 
patients with acute PE. 
 
Clinical Trial Registration: URL: http://www.clinicaltrials.gov. Unique identifier: 
NCT01590342. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Diclofenac for intermediate-risk PE 
Thromb Res 
 
INTRODUCTION 
 
In patients with acute pulmonary embolism (PE), right ventricular (RV) 
dysfunction results from mechanical obstruction of the pulmonary vasculature, 
pulmonary arterial vasoconstriction, and inflammation of the RV muscle (1). 
Hypothesized mechanisms of RV inflammation include the accumulation of 
neutrophils and monocytes in the RV outflow track, and elevated circulating 
concentrations of myeloperoxidase and other inflammatory biomarkers 
associated with PE (2, 3). 
 
Parenteral anticoagulation remains the primary acute treatment for PE (4). 
Heparins inhibit the action of thrombin, allowing the unopposed effect of 
endogenous plasmin to degrade clot volume over a period of days to weeks (5). 
Since the acute development of RV dysfunction in association with acute PE 
increases the risk of death from PE, studies have assessed the efficacy and 
safety of thrombolytic therapy for these patients (6). Fibrinolytic agents allow 
faster clot size reduction than heparins, but they have an increased risk of 
haemorrhage (7). In addition, approximately 16% of patients with PE have a 
contraindication to anticoagulation, and 30% have a contraindication to 
fibrinolysis (8). 
 
Attenuation of the inflammatory response in patients who have acute PE and 
associated with RV dysfunction may improve patient outcomes. A rat model of 
PE by Watts et al suggested that administration of ketorolac reduced RV 
inflammatory genes, reduced neutrophil influx, and improved RV function in the 
setting of experimental PE (9). This study assessed the efficacy of diclofenac for 
improving RV dysfunction in intermediate-risk PE patients who received standard 
anticoagulation. 
 
 
METHODS 
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Study design 
The AINEP trial (NCT01590342) was a single center prospective, randomized, 
blinded, parallel-group, placebo-controlled study that evaluated the hypothesis 
that therapy with diclofenac would improve RV function in patients who had 
intermediate-risk acute PE and associated RV dysfunction. Patients were 
recruited between 2013 and 2016 from a tertiary university hospital in Madrid, 
Spain. The study was conducted in accordance with the Declaration of Helsinki, 
was approved by the local ethics committee, and required written informed 
consent for participation. 
 
Study patients 
Consecutive adult patients who had an objective diagnosis of PE were 
considered for inclusion in the study if they had: 1) onset of symptoms since no 
more than 10 days, 2) normal blood pressure (systolic blood pressure > 100 
mmHg), and 3) echocardiographic RV dysfunction detected within 12 hours after 
the diagnosis of PE. For the diagnosis of PE, confirmatory testing required a high 
probability ventilation-perfusion (V/Q) scintigraphy (10), or a positive contrast-
enhanced, PE-protocol, helical chest multi-detector computerized tomography 
(CT) for PE (11). 
 
Study exclusion criteria consisted of a history of chronic pulmonary hypertension, 
bronchial asthma, or severe heart failure. Patients were also excluded if they had 
had clinically relevant bleeding, major surgery or trauma within the last month, or 
if they had a hemorrhagic diathesis, active peptic ulcer, Crohn’s disease or 
ulcerative colitis, or severe hepatic or renal failure. Exclusion criteria also 
included use of oral anticoagulation in the last two weeks, pregnancy, lactation, 
or less than 30 days post-partum. 
 
Randomization and treatment 
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Eligible patients were randomly allocated in a 1:1 ratio to receive diclofenac or 
placebo. Treatments were randomly allocated at the Pharmacy of Ramon y Cajal 
Hospital (Madrid, Spain) with a computer-generated list of random number in 
blocks of four. Copies of the randomization code were kept in sealed, 
sequentially numbered, opaque envelopes at the pharmacy. 
 
Patients who were assigned to receive diclofenac were given an intravenous (IV) 
infusion of diclofenac (75mg, 3 mL) given over 30 minutes, two doses 12 hours 
apart in the first 24 hours after randomization. Patients assigned to placebo were 
given an IV infusion that had the same volume and appearance as for diclofenac, 
and they had a similar infusion duration and schedule. Diclofenac and placebo 
solutions were provided by the local pharmacy. 
 
All patients received standard anticoagulation with subcutaneous low-molecular-
weight heparin (LMWH) enoxaparin (1 mg/Kg/12 hours). An oral vitamin K 
antagonist was started on the third day after randomization. LWMH was 
discontinued after the INR was at least 2.0 for two consecutive days. 
 
Echocardiography assessment 
The study required that patients undergo TTE within 12 hours after diagnosis of 
PE. Trained and certified local cardiologists, blinded to the patient’s clinical data 
and the time of the echocardiography (i.e., before or after treatment), interpreted 
each echocardiogram, and these measurements were used for analyses. The 
study defined echocardiographic RV dysfunction as the presence of, at least, two 
of the following criteria: i) RV diastolic diameter > 30 mm in the parasternal 
window; ii) RV diameter > left ventricle diameter in the apical or subcostal space; 
iii) RV free wall hypokinesis; and iv) estimated pulmonary artery systolic pressure 
> 30 mm Hg (12). 
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A core laboratory that was blinded to group assignment measured baseline 
RV/LV ratios, and these measures were compared with the data obtained by 
local cardiologists to assess interobserver agreement. 
 
Follow-up and outcome assessment 
Study personnel assessed study participants for death, hemodynamic 
decompensation (or collapse), bleeding, stroke, recurrent PE, and serious 
adverse events for 30 days post-randomization. An independent clinical-events 
committee, whose members were unaware of the treatment-group assignments, 
adjudicated all efficacy and safety outcomes. 
 
The primary efficacy outcome of the study was the resolution of 
echocardiographic RV dysfunction at 48 hours after randomization. The 
secondary efficacy outcome was the resolution of RV dysfunction at 7 days after 
randomization. The primary safety outcome was major bleeding within 7 days 
after randomization. Major bleeding was defined as overt bleeding associated 
with a fall in the hemoglobin level of at least 2.0 g/dl or with transfusion of > 2 
units of red blood cells, with involvement of a critical site (intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compartment syndrome), or with death (13). 
 
Statistical analyses 
Sample size assumptions were based on the Tenecteplase Italian 
Pulmonary Embolism Study (TIPES), in which therapy with weight-adjusted 
intravenous tenecteplase significantly reduced the RV/ left ventricle (LV) ratio at 
24 hours by a mean of 0.31 (standard deviation [SD] 0.20), and therapy with 
unfractionated heparin (UFH) alone resulted in a nonsignificant reduction in 
RV/LV ratio by a mean of 0.10 (SD 0.30) (14). We assumed that diclofenac 
would have an effect similar to tenecteplase for resolution of RV dysfunction, and 
we used the means and SDs of the difference in RV/LV ratio from the 
tenecteplase and heparin groups for sample size calculation. Using a beta of 0.8 
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(power of 80%), and a 2-sided alpha of 0.05, the estimated sample size was 45 
per group. Because of slow recruitment and limited resources, the trial closed in 
December 2016. 
 
Continuous data are presented as mean ± SD or, in case of a skewed 
distribution, as median values with ranges. Comparison of binary data between 
the groups was performed with the Fisher exact test. Within-group comparisons 
of continuous data were performed with the 2-sided paired t test. Within-group 
ordinal data were compared with the 2-sided Wilcoxon signed-rank test. 
Between-group continuous data were compared with the 2-sided unpaired t test 
or Wilcoxon rank sum test. Between-group ordinal data were compared with the 
exact Mantel- Haenszel chi-square test. Interobserver agreement for the 
echocardiographic baseline RV/LV ratio between the investigator and core 
laboratory measurements was assessed by Bland-Altman analysis (15). 
 
 
RESULTS 
 
Patients 
From January 2013 through December 2016, a total of 34 patients were enrolled. 
Of these patients, 17 were randomly assigned to treatment with diclofenac, and 
17 were randomly assigned to placebo (Figure 1). The two treatment groups had 
similar baseline demographic, clinical, and medical history data (Table 1). The 
median age in the study population was 75 years and 65% were women. All 
patients were normotensive at randomization. 
 
Echocardiography 
With all patients having RV dysfunction at randomization, it persisted in 59% 
(95% confidence interval [CI], 33-82%) of the diclofenac group and in 76% (95% 
CI, 50-93%) of the placebo group at 48 hours (Table 2), which did not meet 
statistical significance for the primary efficacy outcome (59% vs. 76%, 
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respectively; P = 0.46). By day 7, the diclofenac and placebo groups had similar 
proportions (35%) of patients who had persistent RV dysfunction (Table 2). 
 
The two treatment groups had similar echocardiographic mean RV end-diastolic 
diameter (45 + 9.8 mm and 40 + 6.3 mm in the diclofenac and placebo groups, 
respectively; P = 0.15) and RV/LV ratio (1.2 + 0.2 and 1.3 + 0.02 in the diclofenac 
and placebo groups, respectively; P = 0.31) at baseline. At 48 hours post-
randomization, the diclofenac and placebo groups did not show a significant 
difference in within-group mean change score for RV end-diastolic dimension 
(0.6 ± 0.7 [diclofenac] vs. 0.3 ± 0.7 [placebo]; P = 0.26), or for RV/LV ratio (0.2 ± 
0.2 vs. 0.2 ± 0.3; P = 0.67) (Figure 2). Similarly, at 7 days post randomization, 
the diclofenac and placebo groups did not show a significant difference in within-
group mean change score for RV end-diastolic dimension (1.1 ± 1.1 [diclofenac] 
vs. 0.9 ± 0.5 [placebo]; P = 0.45) or for RV/LV ratio (0.3 ± 0.3 vs. 0.4 ± 0.3; P = 
0.73). 
 
Safety outcomes 
Only one major bleeding event occurred (Table 3). An 81 year-old patient in the 
placebo group developed cardiovascular collapse 3 days after initially being 
treated with anticoagulant therapy. He received “rescue” thrombolytic therapy. 
Two days later, a major gastrointestinal bleeding event led to discontinuation of 
anticoagulation and placement of an inferior vena cava (IVC) filter. Sixteen days 
after the diagnosis of acute PE, he developed a new symptomatic deep vein 
thrombosis. At 30 days, none of the 34 randomized patients had died. 
 
Interobserver agreement 
In 32 (94%; 95% CI, 80-99%) of 34 analyzed patients, there was agreement 
between investigators and core laboratory for identifying patients with a baseline 
RV/LV ratio > 1. The mean (± SD) difference in the baseline echocardiographic 
RV/LV ratio between investigator and core laboratory measurements was 0.03 ± 
0.10 (Figure 3). 
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DISCUSSION 
 
We conducted the first registered (clinicaltrials.gov) randomized trial of diclofenac 
versus placebo in normotensive patients who had acute symptomatic PE 
associated with RV dysfunction. Between the two randomized treatment groups, 
this study did not detect a statistically significantly greater improvement in the 
proportion of patients who had RV dysfunction at 48 hours or at 7 days after 
randomization. Many patients in both randomized groups had improvements in 
multiple echocardiographic variables related to RV dysfunction at 48 hours, and 
most patients showed such improvement at 7 days after randomization, and 
statistically significant within group improvements occurred for most variables at 
both time points. Since poor enrollment led to early termination of the study, a 
type II error could have occurred, since the study only had a power of 18% to 
detect a difference in the primary outcome. By extrapolation, these data imply 
that a follow-up study in a similar patient population would require 118 
randomized patients in each treatment group to be able to detect a between-
group difference of 17% in the proportion of patients who normalized their 
echocardiographic findings. Thus, this work provides necessary preliminary data 
for a larger and more definitive clinical trial. 
 
This trial emphasizes an important ancillary point about the difficulty of executing 
an acute treatment trial for patients with PE and RV dysfunction. Despite 15 
consecutive hours per day of pre-screening and screening for eligible subjects 
over a five-year period in a large, tertiary treatment center, only 88 of 213 
patients approached were eligible (41%), and only 34 (16% of patients 
approached and 39% of those eligible) agreed to participate. 
 
Supporting the rationale for this study and the non-statistically significant results 
demonstrated in this study, a rat model of PE by Watts et al demonstrated that 
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administration of ketorolac protected RV contractile function in the setting of 
experimental PE (9). Regarding our choice of NSAID, we decided to use 
diclofenac, a nonselective cyclooxygenase (COX)-1 and COX-2 inhibitor (19), 
since COX-2 inhibitors may increase the risk of platelet activation and 
vasoconstriction (16), and studies have demonstrated their association with 
increased mortality in chronic heart failure (17) and myocardial infarction (18). 
We chose to use a dose of diclofenac that studies of analgesia successfully used 
(20, 21). 
 
Regarding the safety of NSAID use among patients with venous 
thromboembolism receiving anticoagulant therapy, studies have shown an 
association between NSAID use and an increased risk of clinically relevant and 
major bleeding (22). Although we did not design this trial of diclofenac vs placebo 
to meet non-inferiority criteria for bleeding complications, we so far feel 
reassured that none of the patients randomized to the 2 doses of diclofenac had 
a major bleeding complication. Of note, the eligibility criteria for the study did 
exclude some of the patients at higher risk for bleeding. 
 
Different groups of investigators have not agreed upon standard definitions for 
echocardiographic findings of RV dysfunction (23). However, previous studies 
supported the use of this study’s primary outcome (24). Similar to a previous trial 
that assessed the efficacy and safety of catheter-directed thrombolysis in 
patients who enrolled with intermediate-risk PE, our data suggested an excellent 
core lab / local clinician agreement of 94% for identifying patients a baseline 
RV/LV ratio > 1. Also supporting the use of RV dysfunction for assessing 
efficacy, our study showed that resolution of RV dysfunction was achieved in 
65% of patients at 7 days in both randomized groups, similar to many 
randomized clinical trials of rt-PA versus heparin that demonstrated a catch-up 
phenomenon in the heparin group, with initially worse hemodynamic parameters 
that later became similar to the thrombolytic group at 1 week of follow-up and 
beyond (25). Futures studies could assess for NSAID effects on other 
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echocardiographic measurements that we did not assess (26). A larger study 
could also have greater power to look for more clinically relevant outcomes such 
as survival. 
 
The most obvious limitations of this study include the inability to successfully 
enroll an adequate number patient in a timely manner, and the subsequently 
reduced power to detect differences between treatment groups. Even if future 
studies confirm the efficacy of diclofenac, the most efficacious and safe drug 
dose and schedule remains unclear. Unfortunately, we did not systematically 
collect cardiac biomarkers assessing myocardial injury (i.e., troponin or heart-
type fatty acid-binding protein [HFABP])) or RV stress (i.e., brain natriuretic 
peptide [BNP]), which could have helped us understand and interpret the results 
of the trial (27). We do not believe that the results of this trial are a consequence 
of inappropriate patient selection. From a biological point of view, the relative 
effect of the intervention (i.e., diclofenac) on the outcome should be the same 
across the spectrum of PE severity, whereas absolute risk reductions will depend 
on the baseline risk of experiencing the outcome. Thus, it seems reasonable to 
support future trials of NSAIDS in patients who have normotensive acute PE 
associated with RV dysfunction and intermediate-risk for death.  
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Figure 1. Patient Flow Diagram 
 
Figure 2. RV/LV ratio at baseline and at 48 hours for each patient in (A) the 
diclofenac group and in (B) the placebo group. 
 
Figure 3. Baseline RV/LV ratio: investigator vs. core laboratory 
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Figure 1. 
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Figure 2. 
 
                 1.2 + 0.2 mm               0.95 + 0.1 mm           1.3 + 0.02 mm               1.04 + 0.2 mm 
 
 
Abbreviations: RV, right ventricle; LV, left ventricle. 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
Diclofenac for intermediate-risk PE 
Thromb Res 
 
Figure 3. 
 
 
 
 
Abbreviations: RV, right ventricle; LV, left ventricle; SD, standard deviation. 
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Table 1. Characteristics of the patients at baseline* 
 
Characteristic Diclofenac 
(N = 17) 
Placebo 
(N = 17) 
 
Demographic data 
Age, years   
   Mean 73.7 + 10.3 67.5 + 17.2 
   Median (interquartile range) 76.0 (69.0-78.0) 69.0 (58.5-80.0) 
Male sex, n (%) 7 (41.2) 5 (29.4) 
Mean weight, Kg 79.9 + 13.2 73.4 + 20.2 
Clinical status 
Systolic blood pressure, mm Hg 132.3 + 12.6 126.0 + 18.9 
Heart rate, beats per minute 98.5 + 26.5 101.7 + 16.0 
Arterial oxyhemoglobin saturation, % 87.7 + 5.2 87.6 + 8.6 
Medical history   
Chronic pulmonary disease, n (%) 0 (0) 0 (0) 
Chronic heart failure, n (%) 0 (0) 0 (0) 
Previous venous thromboembolism, n (%) 1 (5.9) 2 (11.8) 
Active cancer, n (%) 0 (0) 2 (11.8) 
Surgery or major trauma in the previous month, n (%) 2 (11.8) 1 (5.9) 
Immobilization, n (%) 3 (17.6) 4 (23.5) 
Simplified PESI   
Low-risk 5 (29%) 4 (24%) 
High-risk 12 (71%) 13 (76%) 
 
Abbreviations: PESI, Pulmonary Embolism Severity Index. 
 
* Plus–minus values are means ± SD. Between-group differences in the characteristics listed here were not 
significant. 
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Table 2. Echocardiographic laboratory data 
 
 Baseline 48 hours 7 days Difference (improved): 
Baseline-48 hours 
Difference (improved): 
Baseline-7 days 
 Diclofenac Placebo Diclofenac Placebo Diclofenac Placebo Diclofenac Placebo Diclofenac Placebo 
RV dysfunction           
N (%) 17 (100) 17 (100) 10 (59) 13 (76) 6 (35) 6 (35) 7 (41) 4 (23) 11 (65) 11 (65) 
Between group comparison P = 1.0 P = 0.46 P = 1.0 P = 0.46 P = 1.0 
Within group comparison N/A N/A N/A P < 0.01 P = 0.10 P < 0.001 P < 0.001 
 
RV diastolic diameter > 30 
mm* 
          
N (%) 16 (94) 16 (94) 13 (76) 12 (71) 10 (59) 6 (35) 3 (18) 4 (23) 6 (35) 10 (59) 
Between group comparison P = 1.0 P = 1.0 P = 0.30 P = 1.0 P = 0.30 
Within group comparison N/A N/A N/A P = 0.33 P = 0.17 P = 0.04 P < 0.001 
 
RV > LV diameter¶ 
          
N (%) 15 (88) 17 (100) 7 (41) 12 (71) 2 (12) 3 (18) 8 (47) 5 (29) 13 (76) 14 (82) 
Between group comparison P = 0.48 P = 0.17 P = 1.0 P = 0.48 P = 1.0 
Within group comparison N/A N/A N/A P = 0.01 P = 0.04 P < 0.001 P < 0.001 
 
Estimated pulmonary 
artery systolic pressure > 
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30 mm Hg 
N (%) 15 (88) 17 (100) 9 (53) 10 (59) 6 (35) 7 (41) 6 (35) 7 (41) 9 (53) 10 (59) 
Between group comparison P = 0.48 P = 1.0 P =1.0 P = 1.0 P = 1.0 
Within group comparison N/A N/A N/A P = 0.06 P < 0.01 P < 0.01 P < 0.001 
 
Hypokinesis of the RV free 
wall 
          
N (%) 13 (76) 12 (71) 7 (41) 7 (41) 2 (12) 1 (5.9) 6 (35) 5 (29) 11 (65) 11 (65) 
Between group comparison P = 1.0 P = 1.0 P =1.0 P = 1.0 P = 1.0 
Within group comparison N/A N/A N/A P = 0.08 P = 0.17 P < 0.001 P < 0.001 
 
TAPSE, mm 
          
Mean + SD 17.7 + 4.1 16.8 + 4.4 19.8 + 3.8 18.4 + 3.4 20.9 + 3.8 19.7 + 3.3 2.6 + 3.1 1.3 + 1.6 3.2 + 3.6 4.1 + 3.7 
Between group comparison P = 0.53 P = 0.30 P = 0.39 P = 0.14 P = 0.55 
Within group comparison N/A N/A N/A P < 0.001 P < 0.001 P < 0.001 P < 0.001 
 
Abbreviations: RV, right ventricle; N/A, not applicable; LV, left ventricle; TAPSE, tricuspid annular pulmonary systolic excursion; SD, standard deviation. 
 
* Measured in the parasternal window. 
¶
 In the apical or subcostal space. 
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Table 3. Clinical events at 30-days 
 
Clinical event Diclofenac 
(n = 17) 
Placebo 
(n = 17) 
All-cause mortality 0 0 
PE-related mortality 0 0 
Haemodynamic collapse* 0 1
¶
 
Recurrent VTE 0 1
¶
 
Major bleeding 0 1
¶
 
 
Abbreviations: PE, pulmonary embolism; VTE, venous thromboembolism.  
 
* Haemodynamic collapse was defined as a systolic blood pressure <90 mm Hg for at least 15 minutes, 
need for catecholamine administration because of persistent arterial hypotension or shock, need for 
thrombolysis, need for endotracheal intubation, or need for cardiopulmonary resuscitation. 
¶
 All events occurred in the same patient. 
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HIGHLIGHTS 
 
 Anti-inflammatory drugs may facilitate the reversal of RV dysfunction in PE. 
 
 We assessed the efficacy of diclofenac for reversing RV dysfunction in PE. 
 
 Our study is inconclusive as to a potential benefit of diclofenac in PE. 
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